SELLAS Life Sciences reports 'promising' cancer vaccine PhII data; Aridis Pharmaceuticals gets NIH grant to develop vaccine storage tech;

> SELLAS Life Sciences announced that in a Phase II study of its WT1 cancer vaccine in malignant pleural mesothelioma patients, top-line data demonstrated clinical significant increases in overall survival and progression-free survival. Release

> Aridis Pharmaceuticals announced that it has received several National Institutes of Health grants, one of which is to develop technology to encase proteins into room temperature stable formulations for simpler vaccines storage. Release

> An attempt to repeal California's strict vaccination requirements for schoolchildren fell short of signatures. More

Suggested Articles

As COVID-19 vaccines advance, the FDA held an expert hearing Thursday to talk safety, efficacy, distribution plans and vaccine confidence—plus more. 

Moderna, racing ahead with COVID-19 vaccine R&D, completed enrollment for its late-stage trial—and moved one step closer to approval.

Since the FDA released new COVID-19 vaccine guidance, HHS Secretary Alex Azar has discussed firing FDA Commissioner Stephen Hahn, Politico reports.